Suppression of atherosclerotic changes in cholesterol-fed rabbits treated with an oral inhibitor of neutral endopeptidase 24.11 (EC 3.4.24.11)

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 16, Issue 8, 1996, Pages 1080-1087

  Kugiyama, Kiyotaka ^a   Sugiyama, Seigo ^a   Matsumura, Toshiyuki ^a   Ohta, Yasutaka ^a   Doi, Hideki ^a   Yasue, Hirofumi ^a  

^a KUMAMOTO UNIV SCHOOL OF MEDICINE   (Japan)

Author keywords

atherosclerosis; C type natriuretic peptide; endothelium; endothelium dependent relaxation; neutral endopeptidase 24.11

Indexed keywords

CANDOXATRIL; MEMBRANE METALLOENDOPEPTIDASE; NATRIURETIC PEPTIDE TYPE C; SUBSTANCE P;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL DIET; ENZYME ACTIVITY; LIPID ANALYSIS; MALE; NONHUMAN; PRIORITY JOURNAL; RABBIT; VASCULAR ENDOTHELIUM;

EID: 0029816097     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.16.8.1080     Document Type: Article

References (42)

1. Roques BP, Noble F, Dauge V, Fournie-Zaluski MC, Beaumont A. Neutral endopeptidase 24.11: structure, inhibition, and experimental and clinical pharmacology. Pharmacol Rev. 1993;45:87-146.
2. Erdos EG, Skidgel RA. Neutral endopeptidase 24.11 (enkephalinase) and related regulators of peptide hormones. FASEB J. 1989;3:145-151.
3. Nadel JA. Decreased neutral endopeptidases: possible role in inflammatory diseases of airways. Lung. 1990;suppl:123-127.
4. Shipp MA, Stefano GB, Switzer SN, Griffin JD, Reinherz EL. CD10 (CALLA)/neutral endopeptidase 24.11 modulates inflammatory peptide-induced changes in neutrophil morphology, migration, and adhesion proteins and is itself regulated by neutrophil activation. Blood. 1991;78:1834-1841.
5. Gafford JT, Skidgel RA, Erdos EG, Hersh LB. Human kidney "enkephalinase," a neutral metalloendopeptidase that cleaves active peptides. Biochemistry. 1983;22:3265-3271.
6. Cortes CL, Huang H, Vicart P, Gase JM, Paulin D, Corvol P. Identification and characterization of neutral endopeptidase in endothelial cells from venous or arterial origins. J Biol Chem. 1992;267:14012-14018.
7. Soleilhac JM, Lucas E, Beaumont A, Turcaud S, Michel JB, Ficheux D, Fournie-Zaluski MC, Roques BP. A 94-kDa protein, identified as neutral endopeptidase-24.11, can inactivate atrial natriuretic peptide in the vascular endothelium. Mol Pharmacol. 1992;41:609-614.
8. Yaksh TL, Sabbe MB, Lucas D, Mjanger E, Chipkin RE. Effects of [N-(L-(1-carboxy-2-phenyl)ethyl]-L-phenylalanyl-β-alanine (SCH32615), a neutral endopeptidase (enkephalinase) inhibitor, on levels of enkephalin, encrypted enkephalins and substance P in cerebrospinal fluid and plasma of primates. J Pharmacol Exp Ther. 1991;256:1033-1041.
9. Gardiner SM, Kemp PA, Bennett T. Effects of the neutral endopeptidase inhibitor, SQ 28,603, on regional haemodynamic responses to atrial natriuretic peptide or proendothelin-1 [1-38] in conscious rats. Br J Pharmacol. 1992;106:180-186.
10. Suzuki E, Hirata Y, Matsuoka H, Sugimoto T, Hayakawa H, Sugimoto T, Kangawa K, Minamino N, Matsuo H. Characterization of atrial natriuretic peptide in urine from rats treated with a neutral endopeptidase inhibitor. Biochem Biophys Res Commun. 1992;182:1270-1276.
11. Richards AM, Wittert GA, Espiner EA, Yandle TG, Ikram H, Frampton C. Effect of inhibition of endopeptidase 24.11 on responses to angiotensin II in human volunteers. Circ Res. 1992;71:1501-1507.
12. Loesch A, Burnstock G. Ultrastructural localization of serotonin and substance P in vascular endothelial cells of rat femoral and mesenteric arteries. Anat Embryol (Berl). 1988;178:137-142.
13. Saed GM, Carretero OA, MacDonald RJ, Scicli AG. Kallikrein messenger RNA in rat arteries and veins. Circ Res. 1990;67:510-516.
14. Furchgott RF, Vanhoutte PM. Endothelium-derived relaxing and contracting factors. FASEB J. 1989;3:2007-2018.
15. D'Orleans-Juste P, de Nucci G, Vane JR. Kinins act on B1 or B2 receptors to release conjointly endothelium-derived relaxing factor and prostacyclin from bovine aortic endothelial cells. Br J Pharmacol. 1989;96:920-926.
16. Bath PMW, Hassall DG, Gladwin AM, Palmer RMJ, Martin JF. Nitric oxide and prostacyclin: divergence of inhibitory effects on monocyte chemotaxis and adhesion to endothelium in vitro. Arterioscler Thromb. 1991;11:254-260.
17. De Nucci G, Gryglewski RJ, Warner TD, Vane JR. Receptor-mediated release of endothelium-derived relaxing factor and prostacyclin from bovine aortic endothelial cells is coupled. Proc Natl Acad Sci U S A. 1988;85:2334-2338.
18. Farhy RD, Ho KL, Carretero OA, Scicli AG. Kinins mediate the antiproliferative effect of ramipril in rat carotid artery. Biochem Biophys Res Commun. 1992;182:283-288.
19. Sudoh T, Minamino N, Kangawa K, Matsuo H. C-type natriuretic peptide (CNP): a new member of natriuretic peptide family identified in porcine brain. Biochem Biophys Res Commun. 1990;168:863-870.
20. Suga S, Nakao K, Itoh H, Komatsu Y, Ogawa Y, Hama N, Imura H. Endothelial production of C-type natriuretic peptide and its marked augmentation by transforming growth factor-β: possible existence of "vascular natriuretic peptide system." J Clin Invest. 1992;90:1145-1149.
21. Stingo AJ, Claveli AL, Heublein DM, Wei CM, Pittelkow MR, Burnett JC. Presence of C-type natriuretic peptide in cultured human endothelial cells and plasma. Am J Physiol. 1992;263:H1318-H1321.
22. Wei CM, Hu S, Miller VM, Burnett JC. Vascular actions of C-type natriuretic peptide in isolated porcine coronary arteries and coronary vascular smooth muscle cells. Biochem Biophys Res Commun. 1994;205:765-771.
23. Furuya M, Yoshida M, Hayashi Y, Ohnuma N, Minamino N, Kangawa K, Matsuo H. C-type natriuretic peptide is a growth inhibitor of rat vascular smooth muscle cells. Biochem Biophys Res Commun. 1991;177:927-931.
24. Furuya M, Aisaka K, Miyazaki T, Honbou N, Kawashima K, Ohno T, Tanaka S, Minamino N, Kangawa K, Matsuo H. C-type natriuretic peptide inhibits intimai thickening after vascular injury. Biochem Biophys Res Commun. 1993;193:248-253.
25. Kenny AJ, Bourne A, Ingram J. Hydrolysis of human and pig brain natriuretic peptides, urodilatin, C-type natriuretic peptide and some C-receptor ligands by endopeptidase-24.11. Biochem J. 1993;291:83-88.
26. Bevan EG, Connell JMC, Doyle J, Carmichael HA, Davies DL, Lorimer AR, McInnes GT. Candoxatril, a neutral endopeptidase inhibitor: efficacy and tolerability in essential hypertension. J Hypertens. 1992;10:607-613.
27. Richards M, Espiner E, Frampton C, Ikram H, Yandle TG, Sopwith M, Cussans N. Inhibition of endopeptidase 24.11 in humans: renal and endocrine effects. Hypertension. 1990;16:269-276.
28. Chan CT, Wells H, Kramsch DM. Suppression of calcific fibrous-fatty plaque formation in rabbits by agents not affecting elevated serum cholesterol levels. Circ Res. 1978;43:115-125.
29. Lowry OH, Rosebrough NY, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. JBiol Chem. 1951;193:265-275.
30. Vijayaraghavan J, Scicli AG, Carretero OA, Slaughter C, Moomaw C, Hersh LB. The hydrolysis of endothelins by neutral endopeptidase 24.11 (enkephalinase). J Biol Chem. 1990;265:14150-14155.
31. Sugiyama S, Kugiyama K, Ohgushi M, Fujimoto K, Yasue H. Lysophosphatidylcholine in oxidized low-density lipoprotein increases endothelial susceptibility to polymorphonuclear leukocyte-induced endothelial dysfunction in porcine coronary arteries: role of protein kinase C. Circ Res. 1994;74:565-575.
32. Schwartz JC, Gros C, Lecomte JM, Bralet J. Enkephalinase (EC 3.4.24.11) inhibitors: protection of endogenous ANF against inactivation and potential therapeutic applications. Life Sci. 1990;47:1279-1297.
33. King KA, Hua J, Torday JS, Drazen JM, Graham SA, Shipp MA, Sunday ME. CD10/neutral endopeptidase 24.11 regulates fetal lung growth and maturation in utero by potentiating endogenous bombesin-like peptides. J Clin Invest. 1993;91:1969-1973.
34. Piedimonte G, Nadel JA, Long CS, Hoffman JIE. Neutral endopeptidase in the heart: neutral endopeptidase inhibition prevents isoproterenol-induced myocardial hypoperfusion in rats by reducing bradykinin degradation. Circ Res. 1994;75:770-779.
35. Munzel T, Kurz S, Holtz J, Busse R, Steinhauer H, Just H, Drexler H. Neurohumoral inhibition and hemodynamic unloading during prolonged inhibition of ANF degradation in patients with severe chronic heart failure. Circulation. 1992;86:1089-1098.
36. Ohyama Y, Miyamoto K, Morishita Y, Matsuda Y, Saito Y, Minamino N, Kangawa K, Matsuo H. Stable expression of natriuretic peptide receptors: effects of HS-142-1, a non-peptide ANP antagonist. Biochem Biophys Res Commun. 1992;189:336-342.
37. Minamino N, Aburaya M, Kojima M, Miyamoto K, Kangawa K, Matsuo H. Distribution of C-type natriuretic peptide and its messenger RNA in rat central nervous system and peripheral tissue. Biochem Biophys Res Commun. 1993;197:326-335.
38. Campbell DJ, Kladis A, Duncan AM. Bradykinin peptides in kidney, blood, and other tissues of the rat. Hypertension. 1993;21:155-165.
39. Carretero OA, Scicli AG. Local hormonal factors (intracrine, autocrine, and paracrine) in hypertension. Hypertension. 1991;18(suppl I):I-58-I-69.
40. Suga S, Nakao K, Mukoyama M, Arai H, Hosoda K, Ogawa Y, Imura H. Characterization of natriuretic peptide receptors in cultured cells. Hypertension. 1992;19:762-765.
41. Seymour AA, Norman JA, Asaad MM, Fennell SA, Swerdel JN, Little DK, Dorso CR. Renal and depressor effects of SQ 29,072, a neutral endopeptidase inhibitor, in conscious hypertensive rats. J Cardiovasc Pharmacol. 1990;16:163-172.
42. Sybertz EJ, Chiu PJS, Vemulapalli S, Watkins R, Haslanger MF. Atrial natriuretic factor-potentiating and antihypertensive activity of SCH 34826: an orally active neutral metalloendopeptidase inhibitor. Hypertension. 1990;15:152-161.